(AXON) - Earnings & Price History

AXON: - 5.3, $579.56M, 0.06 (1.15%)

Sector: Healthcare - Industry: Biotechnology

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquiring, developing, and commercializing novel therapeutics for the treatment of dementia in the United States and Europe. Its lead product candidate, intepirdine, is a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimers disease and in Phase II clinical trial for treating dementia with Lewy bodies (DLB). The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia and REM behavior disorder in patients with DLB. In addition, it focuses on developing a pipeline of product candidates to address the cognitive, behavioral, and functional aspects of dementia. The company was formerly known as Roivant Neurosciences Ltd. a

Past AXON reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-02-10BMO-0.4612.6712.8312.8312.4712.96-1.25%-1.25%315.03K
2017-02-09BMO-0.4612.8312.8912.8612.8113.15-0.23%-0.23%-0.47%236.59K
2017-02-08BMO-0.4612.8912.9112.7912.5513.18-0.93%0.78%-0.15%549.63K
2017-02-07BMO-0.4612.9112.9713.0612.8313.240.69%-1.15%-0.46%286.69K
2016-11-03BMO-0.3711.2612.0312.111.2512.180.58%▲-6.94%-6.40%271.67K
2016-11-02BMO-0.3712.0312.5112.5111.9912.73-3.84%-3.84%271.89K
2016-11-01BMO-0.3712.5112.3112.1912.0212.65-0.97%▲2.63%1.62%311.93K
2016-10-31BMO-0.3712.3112.7212.6612.312.68-0.47%▲-2.76%-3.22%203.59K
2016-06-06BMO-0.313.1512.9812.9212.7313.31-0.46%1.78%1.31%445.00K
2015-11-02AMC-0.2415.4313.3713.3913.2315.680.15%▲15.24%15.41%873.55K

Login | Register
Saturday Nov 17, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades